Ministers are reviewing a controversial medicine tax that pharmaceutical companies say makes Britain 'uninvestable' as part ...

Drugmakers in the US have been exempted from tariffs but the pills and capsules may soon hit the fan. They are lobbying US president Donald Trump for more time to absorb tariffs and perhaps move their ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The first-quarter results of the healthcare sector have been impressive, with earnings of 85% of the sector participants that have reported so far up 46.8% on 8% revenue growth. The earnings beat ...

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

Drugmaker Viatris beat Wall Street estimates for first-quarter profit and revenue on Thursday, helped by sales of its branded drugs in China.

I look forward to working with the team to reach new corporate and clinical milestones,” added Dieter Weinand, Chairman of ...

Pfizer Chief Executive Albert Bourla is equally worried. While agreeing on the need for a more secure drug supply, he doubts ...

Manufacturing Digital's top 10 biggest pharmaceutical manufacturers delivering innovative healthcare and improved patient ...

In 2023, nearly 1 in 4 US adults were living with chronic pain, and 8.5% experienced pain severe enough to limit daily life ...

ORIC Pharmaceuticals, Inc.’s ORIC share price has dipped by 7.54%, which has investors questioning if this is right time to buy.

Attempts to address the issue of accelerating the pace of switches aren’t new. But without innovative ways to spur ...